Research & Reports
Sep 20, 2026•1 min read
Daraxonrasib Demonstrates Tumor Reduction in NSCLC in Early Study
Within a week of U.S. approval for pancreatic cancer, daraxonrasib showed tumor shrinkage in over 30% of non‑small cell lung cancer patients in a small trial.
Research & Reports
Sep 13, 2026•1 min read
Hecto Group develops AI device for early lung cancer detection and recurrence prediction
Hecto Group’s AI unit, HAI, joined the OnKoTECT consortium led by Seoul National University Bundang Hospital to develop an AI medical device for early lung cancer diagnosis and post‑surgery recurrence prediction, under a Ministry of Trade, Industry and Energy digital‑health project.
Research & Reports
Sep 1, 2026•1 min read
Lung Cancer 5‑Year Survival in Korea Jumps to 42.5% Amid EGFR‑TKI Advances
Korea’s 5‑year lung cancer survival rate rose to 42.5% in 2023, driven by targeted therapies and the 10‑year anniversary of third‑gen EGFR‑TKI Tagrisso.